研究業績

ページタイトル画像

乳腺外科

主な論文業績

2023

1. Hayama S, Nakamura R, Ishige T, Sangai T, Sakakibara M, Fujimoto H, Ishigami E, Masuda T, Nakagawa A, Teranaka R, Ota S, Itoga S, Yamamoto N, Nagashima T, Otsuka M. The impact of PIK3CA mutations and PTEN expression on the effect of neoadjuvant therapy for postmenopausal luminal breast cancer patients. BMC Cancer 23: 384, 2023.

2. Teranaka R, Fujimoto H, Masuda T, Kuroda M, Aoyagi Y, Nagashima T, Takada M, Sakakibara J, Yamada H, Yamamoto H, Kubota Y, Ohtsuka M. Ex vivo dual gene therapy using human adipocytes secreting anti‑HER2 antibody on HER2‑positive xenograft tumor models. Breast Cancer 30: 1018–1027, 2023.

3. Yu M, Takada M, Yamada H, Fujimoto H, Sakakibara J, Yamamoto H, Nagashima T, Ohtsuka M. Less necessity of adjuvant S-1 treatment in non-monarchE-eligible patients. Cancer Medicine 12: 13193–91, 2023.

4. Sakakibara J, Nagashima T, Fujimoto H, Takada M, Ohtsuka M. A review of MRI (CT)/US fusion imaging in treatment of breast cancer. J Med Ultrason 50: 367-373, 2023.

5. DiDonna SC, Nagornyuk A, Adhikari N, Takada M, Takaku M. P4HTM: A Novel Downstream Target of GATA3 in Breast Cancer. Res Sq 2023 Feb 28:rs.3.rs-2622989.

6. Misawa S, Denda T, Kodama S, Suzuki T, Naito Y, Kogawa T, Takada M, Suichi T, Shiosakai K, Kuwabara S. Efficacy and safety of mirogabalin for chemotherapy-induced peripheral neuropathy: a prospective single-arm trial (MiroCIP study).; MiroCIP study group. BMC Cancer. 2023 Nov 11;23(1):1098.

7. Akita S, Tokumoto H, Yamaji Y, Kosaka K, Arai M, Ando N, Maei H, Kubota Y, Fujimoto H, Mitsukawa N. Scarless Donor Site for Breast Reconstruction by Endoscopy-assisted Extended Latissimus Dorsi Flap plus Lipofilling. Plast Reconstr Surg. 2023 May 23.

8. Matsubara S, Ozawa S, Kameyama S, Takada M, Tanaka G. Optimization of suction device installation for prevention of SARS-CoV-2 infection in otorhinolaryngology examination rooms Advanced Biomedical Engineering (in press)

2022

1. Takada M, Fukushima T, Ozawa S, Matsubara S, Suzuki T, Fukumoto I, Hanazawa T, Nagashima T, Uruma R, Otsuka M, Tanaka G. Infection control for COVID-19 in hospital examination room. Sci Rep. 2022 Oct 29;12(1):18230.

2. Surov A, Pech M, Meyer HJ, Bitencourt AGV, Fujimoto H, Baxter GC, Santamaría G, Gilbert FJ, Wienke A. Evaluation of pretreatment ADC values as predictors of treatment response to neoadjuvant chemotherapy in patients with breast cancer - a multicenter study. Cancer Imaging 22: 68-75, 2022

2021

1. Takada M, Tanaka G, Hashimoto H, Hirai Y, Fukushima T, Nagashima T, Otsuka M, Imazeki F. Practical approach to prevent COVID-19 infection at breast cancer screening. Breast Cancer 28: 969-976, 2021.

2. Miyoshi T, Yamaguchi S, Fujimoto H, Yoshioka S, Shiobara M, Wakatsuki K, Suda K, Miyazawa K, Aida T, Watanabe Y, Otsuka M. A new method to optimize resection area using a radiation treatment planning system and deformable image registration for breast-conserving surgery after neoadjuvant chemotherapy. Eur J Surg Oncol 47, 789-795, 2021.

3. Arai M, Sakakibara M, Nagashima T, Otsuka M. Biomarker expression for Th17 cells along with tumor progression and lymph node invasion in patients with breast cancer. Chiba Medical J 97: 39-48, 2021.

4. Yamashita T, Kawaguchi H, Masuda N, Kitada M, Narui K, Hattori M, Yoshinami T, Matsunami N, Yanagihara K, Kawasoe T, Nagashima T, Bando H, Yano H, Hasegawa Y, Nakamura R, Kashiwaba M, Morita S, Ohno S, Toi M. Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2positive advanced or metastatic breast cancer: A multicenter, single arm, phase II study (JBCRG-M03 study)". Investigational New Drugs 39, 217-225, 2021.

5. Futamura M, Oba M, Masuda N, Bando H, Yamamoto Y, Kin T, Saeki T, Nagashima T, Kuwayama T, Toh U, Hirano A, Inokuchi M, Yamagami K, Mizuno Y, Kojima Y, Nakayama T, Yasojima H, Okada M, Ohno S. Meta-analysis of nanoparticle albumin-bound paclitaxel used as neoadjuvant chemotherapy for operable breast cancer based on individual patient data (JBCRG-S01 study). Breast Cancer 28: 1023–1037, 2021.

6. Sasaki K, Takano S, Tomizawa S, Miyahara Y, Furukawa K, Takayashiki T, Kuboki S, Takada M, Ohtsuka M. C4b-binding protein α-chain enhances antitumor immunity by facilitating the accumulation of tumor-infiltrating lymphocytes in the tumor microenvironment in pancreatic cancer. J Exp Clin Cancer Res 40: 212, 2021.

7. Shimazaki R, Takano S, Satoh M, Takada M, Miyahara Y, Sasaki K, Yoshitomi H, Kagawa S, Furukawa K, Takayashiki T, Kuboki S, Sogawa K, Motohashi S, Nomura F, Miyazaki M, Ohtsuka M. Complement factor B regulates cellular senescence and is associated with poor prognosis in pancreatic cancer. Cell Oncol 44: 937-950, 2021.

2020

1. Nakagawa A, Fujimoto H, Nagashima T, Sangai T, Takada M, Masuda T, Teranaka R, Ota S, Matsushima J, Akita S, Ohtsuka M. Histological features of skin and subcutaneous tissue in patients with breast cancer who have received neoadjuvant chemotherapy and their relationship to post-treatment edema. Breast Cancer. 2020 Jan;27(1):77-84.

2. Fujimoto H, Shiina N, Nagashima T, Sangai T, Sakakibara J, Takada M, Teranaka R, Takishim H, Kawasaki Y, Ohtsuka M. Oncoplastic breast-conserving surgery using chest wall perforator flaps: three dimensional quantitative analysis of the percentage of breast volume excised and changes over time in flap volume. J Surg Oncol. 2020 Feb;121(2):216-223.

3. Masuda T, Fujimoto H, Teranaka R, Kuroda M, Aoyagi Y, Nagashima T, Sangai T, Takada M, Nakagawa A, Kubota Y, Yokote K, Ohtsuka M. Anti-HER2 antibody therapy using gene-transduced adipocytes for HER2-positive breast cancer. Breast Cancer Res Treat. 2020 Apr;180(3):625-634.

4. Akita S, Yamaji, Y, Takeuchi N, Wakai K, Azuma K, Nakagawa A, Fujimoto H, Sangai T, Nagashima T, Mitsukawa N, Ikehara Y. Detection of non-palpable tiny axillary lymph nodes surrounded by adipose tissue. Lymphat Res Biol. 2020 Oct;18(5):455-463.

5. Liao C, Zhang Y, Fan C, Herring LE, Liu J, Locasale JW, Takada M, Zhou J, Zurlo G, Hu L, Simon JM, Ptacek TS, Andrianov VG, Loza E, Peng Y, Yang H, Perou CM, Zhang Q. Identification of BBOX1 as a Therapeutic Target in Triple-Negative Breast Cancer. Cancer Discov. 2020 Jul 20.

2019

1. Ishigami E, Sakakibara M, Sakakibara J, Masuda T, Fujimoto H, Hayama S, Nagashima T, Sangai T, Nakagawa A, Nakatani Y, Otsuka M. Coexistence of regulatory B cells and regulatory T cells in tumor-infiltrating lymphocytes aggregates is a prognostic factor in patients with breast cancer. Breast Cancer. 2019 Mar;26(2):180-189.

2. Ota J, Yokota H, Takishima H, Takada A, Irie R, Suzuki Y, Nagashima T, Horikoshi T, Chida K, Masuda Y, Uno T. (2019) Breast exposure reduction 1using organ-effective modulation on chest CT in Asian women. Eur J Radiol 119, 108651.

3. Zurlo G, Liu X, Takada M, Fan C, Simon JM, Ptacek TS, Rodriguez J, von Kriegsheim A, Liu J, Locasale JW, Robinson A, Zhang J, Holler JM, Kim B, Zikánová M, Bierau J, Xie L, Chen X, Li M, Perou CM, Zhang Q. Prolyl hydroxylase substrate adenylosuccinate lyase is an oncogenic driver in triple negative breast cancer. Nat Commun. 2019 Nov 15;10(1):5177.

4. Sugiura K, Mishima T, Takano S, Yoshitomi H, Furukawa K, Takayashiki T, Kuboki S, Takada M, Miyazaki M, Ohtsuka M. The Expression of Yes-Associated Protein (YAP) Maintains Putative Cancer Stemness and Is Associated with Poor Prognosis in Intrahepatic Cholangiocarcinoma. Am J Pathol. 2019 Sep;189(9):1863-1877.

5. Watanabe T, Yagata H, Saito M, Okada H, Yajima T, Tamai N, Yoshida Y, Takayama T, Imai H, Nozawa K, Sangai T, Yoshimura A, Hasegawa Y, Yamaguchi T, Shimozuma K, Ohashi Y. A multicenter survey of temporal changes in chemotherapy-induced hair loss in breast cancer patients. PLoS One. 2019 Jan 9;14(1):e0208118.